Antibody-drug Conjugates-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data
Report Summary
Antibody-drug Conjugates-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Antibody-drug Conjugates industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Antibody-drug Conjugates 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Antibody-drug Conjugates worldwide and market share by regions, with company and product introduction, position in the Antibody-drug Conjugates market
Market status and development trend of Antibody-drug Conjugates by types and applications
Cost and profit status of Antibody-drug Conjugates, and marketing status
Market growth drivers and challenges
The report segments the global Antibody-drug Conjugates market as:
Global Antibody-drug Conjugates Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Antibody-drug Conjugates Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Seattle Genetics technology
ImmunoGen technology
Immunomedics technology
Global Antibody-drug Conjugates Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
IgG1 antibodies
HER2 antibodies
Global Antibody-drug Conjugates Market: Manufacturers Segment Analysis (Company and Product introduction, Antibody-drug Conjugates Sales Volume, Revenue, Price and Gross Margin):
F. Hoffmann-La Roche
Seattle Genetics
Takeda Pharmaceuticals
AbbVie
AbGenomics
ADC Therapeutics
Agensys
ALMAC Group
Ambrx
Astellas Pharma
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Antibody-drug Conjugates-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Antibody-drug Conjugates industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Antibody-drug Conjugates 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Antibody-drug Conjugates worldwide and market share by regions, with company and product introduction, position in the Antibody-drug Conjugates market
Market status and development trend of Antibody-drug Conjugates by types and applications
Cost and profit status of Antibody-drug Conjugates, and marketing status
Market growth drivers and challenges
The report segments the global Antibody-drug Conjugates market as:
Global Antibody-drug Conjugates Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Antibody-drug Conjugates Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Seattle Genetics technology
ImmunoGen technology
Immunomedics technology
Global Antibody-drug Conjugates Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
IgG1 antibodies
HER2 antibodies
Global Antibody-drug Conjugates Market: Manufacturers Segment Analysis (Company and Product introduction, Antibody-drug Conjugates Sales Volume, Revenue, Price and Gross Margin):
F. Hoffmann-La Roche
Seattle Genetics
Takeda Pharmaceuticals
AbbVie
AbGenomics
ADC Therapeutics
Agensys
ALMAC Group
Ambrx
Astellas Pharma
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF ANTIBODY-DRUG CONJUGATES
1.1 Definition of Antibody-drug Conjugates in This Report
1.2 Commercial Types of Antibody-drug Conjugates
1.2.1 Seattle Genetics technology
1.2.2 ImmunoGen technology
1.2.3 Immunomedics technology
1.3 Downstream Application of Antibody-drug Conjugates
1.3.1 IgG1 antibodies
1.3.2 HER2 antibodies
1.4 Development History of Antibody-drug Conjugates
1.5 Market Status and Trend of Antibody-drug Conjugates 2013-2023
1.5.1 Global Antibody-drug Conjugates Market Status and Trend 2013-2023
1.5.2 Regional Antibody-drug Conjugates Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Antibody-drug Conjugates 2013-2017
2.2 Sales Market of Antibody-drug Conjugates by Regions
2.2.1 Sales Volume of Antibody-drug Conjugates by Regions
2.2.2 Sales Value of Antibody-drug Conjugates by Regions
2.3 Production Market of Antibody-drug Conjugates by Regions
2.4 Global Market Forecast of Antibody-drug Conjugates 2018-2023
2.4.1 Global Market Forecast of Antibody-drug Conjugates 2018-2023
2.4.2 Market Forecast of Antibody-drug Conjugates by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Antibody-drug Conjugates by Types
3.2 Sales Value of Antibody-drug Conjugates by Types
3.3 Market Forecast of Antibody-drug Conjugates by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Antibody-drug Conjugates by Downstream Industry
4.2 Global Market Forecast of Antibody-drug Conjugates by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Antibody-drug Conjugates Market Status by Countries
5.1.1 North America Antibody-drug Conjugates Sales by Countries (2013-2017)
5.1.2 North America Antibody-drug Conjugates Revenue by Countries (2013-2017)
5.1.3 United States Antibody-drug Conjugates Market Status (2013-2017)
5.1.4 Canada Antibody-drug Conjugates Market Status (2013-2017)
5.1.5 Mexico Antibody-drug Conjugates Market Status (2013-2017)
5.2 North America Antibody-drug Conjugates Market Status by Manufacturers
5.3 North America Antibody-drug Conjugates Market Status by Type (2013-2017)
5.3.1 North America Antibody-drug Conjugates Sales by Type (2013-2017)
5.3.2 North America Antibody-drug Conjugates Revenue by Type (2013-2017)
5.4 North America Antibody-drug Conjugates Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Antibody-drug Conjugates Market Status by Countries
6.1.1 Europe Antibody-drug Conjugates Sales by Countries (2013-2017)
6.1.2 Europe Antibody-drug Conjugates Revenue by Countries (2013-2017)
6.1.3 Germany Antibody-drug Conjugates Market Status (2013-2017)
6.1.4 UK Antibody-drug Conjugates Market Status (2013-2017)
6.1.5 France Antibody-drug Conjugates Market Status (2013-2017)
6.1.6 Italy Antibody-drug Conjugates Market Status (2013-2017)
6.1.7 Russia Antibody-drug Conjugates Market Status (2013-2017)
6.1.8 Spain Antibody-drug Conjugates Market Status (2013-2017)
6.1.9 Benelux Antibody-drug Conjugates Market Status (2013-2017)
6.2 Europe Antibody-drug Conjugates Market Status by Manufacturers
6.3 Europe Antibody-drug Conjugates Market Status by Type (2013-2017)
6.3.1 Europe Antibody-drug Conjugates Sales by Type (2013-2017)
6.3.2 Europe Antibody-drug Conjugates Revenue by Type (2013-2017)
6.4 Europe Antibody-drug Conjugates Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Antibody-drug Conjugates Market Status by Countries
7.1.1 Asia Pacific Antibody-drug Conjugates Sales by Countries (2013-2017)
7.1.2 Asia Pacific Antibody-drug Conjugates Revenue by Countries (2013-2017)
7.1.3 China Antibody-drug Conjugates Market Status (2013-2017)
7.1.4 Japan Antibody-drug Conjugates Market Status (2013-2017)
7.1.5 India Antibody-drug Conjugates Market Status (2013-2017)
7.1.6 Southeast Asia Antibody-drug Conjugates Market Status (2013-2017)
7.1.7 Australia Antibody-drug Conjugates Market Status (2013-2017)
7.2 Asia Pacific Antibody-drug Conjugates Market Status by Manufacturers
7.3 Asia Pacific Antibody-drug Conjugates Market Status by Type (2013-2017)
7.3.1 Asia Pacific Antibody-drug Conjugates Sales by Type (2013-2017)
7.3.2 Asia Pacific Antibody-drug Conjugates Revenue by Type (2013-2017)
7.4 Asia Pacific Antibody-drug Conjugates Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Antibody-drug Conjugates Market Status by Countries
8.1.1 Latin America Antibody-drug Conjugates Sales by Countries (2013-2017)
8.1.2 Latin America Antibody-drug Conjugates Revenue by Countries (2013-2017)
8.1.3 Brazil Antibody-drug Conjugates Market Status (2013-2017)
8.1.4 Argentina Antibody-drug Conjugates Market Status (2013-2017)
8.1.5 Colombia Antibody-drug Conjugates Market Status (2013-2017)
8.2 Latin America Antibody-drug Conjugates Market Status by Manufacturers
8.3 Latin America Antibody-drug Conjugates Market Status by Type (2013-2017)
8.3.1 Latin America Antibody-drug Conjugates Sales by Type (2013-2017)
8.3.2 Latin America Antibody-drug Conjugates Revenue by Type (2013-2017)
8.4 Latin America Antibody-drug Conjugates Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Antibody-drug Conjugates Market Status by Countries
9.1.1 Middle East and Africa Antibody-drug Conjugates Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Antibody-drug Conjugates Revenue by Countries (2013-2017)
9.1.3 Middle East Antibody-drug Conjugates Market Status (2013-2017)
9.1.4 Africa Antibody-drug Conjugates Market Status (2013-2017)
9.2 Middle East and Africa Antibody-drug Conjugates Market Status by Manufacturers
9.3 Middle East and Africa Antibody-drug Conjugates Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Antibody-drug Conjugates Sales by Type (2013-2017)
9.3.2 Middle East and Africa Antibody-drug Conjugates Revenue by Type (2013-2017)
9.4 Middle East and Africa Antibody-drug Conjugates Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF ANTIBODY-DRUG CONJUGATES
10.1 Global Economy Situation and Trend Overview
10.2 Antibody-drug Conjugates Downstream Industry Situation and Trend Overview
CHAPTER 11 ANTIBODY-DRUG CONJUGATES MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Antibody-drug Conjugates by Major Manufacturers
11.2 Production Value of Antibody-drug Conjugates by Major Manufacturers
11.3 Basic Information of Antibody-drug Conjugates by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Antibody-drug Conjugates Major Manufacturer
11.3.2 Employees and Revenue Level of Antibody-drug Conjugates Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 ANTIBODY-DRUG CONJUGATES MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 F. Hoffmann-La Roche
12.1.1 Company profile
12.1.2 Representative Antibody-drug Conjugates Product
12.1.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche
12.2 Seattle Genetics
12.2.1 Company profile
12.2.2 Representative Antibody-drug Conjugates Product
12.2.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of Seattle Genetics
12.3 Takeda Pharmaceuticals
12.3.1 Company profile
12.3.2 Representative Antibody-drug Conjugates Product
12.3.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of Takeda Pharmaceuticals
12.4 AbbVie
12.4.1 Company profile
12.4.2 Representative Antibody-drug Conjugates Product
12.4.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of AbbVie
12.5 AbGenomics
12.5.1 Company profile
12.5.2 Representative Antibody-drug Conjugates Product
12.5.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of AbGenomics
12.6 ADC Therapeutics
12.6.1 Company profile
12.6.2 Representative Antibody-drug Conjugates Product
12.6.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of ADC Therapeutics
12.7 Agensys
12.7.1 Company profile
12.7.2 Representative Antibody-drug Conjugates Product
12.7.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of Agensys
12.8 ALMAC Group
12.8.1 Company profile
12.8.2 Representative Antibody-drug Conjugates Product
12.8.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of ALMAC Group
12.9 Ambrx
12.9.1 Company profile
12.9.2 Representative Antibody-drug Conjugates Product
12.9.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of Ambrx
12.10 Astellas Pharma
12.10.1 Company profile
12.10.2 Representative Antibody-drug Conjugates Product
12.10.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of Astellas Pharma
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTIBODY-DRUG CONJUGATES
13.1 Industry Chain of Antibody-drug Conjugates
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF ANTIBODY-DRUG CONJUGATES
14.1 Cost Structure Analysis of Antibody-drug Conjugates
14.2 Raw Materials Cost Analysis of Antibody-drug Conjugates
14.3 Labor Cost Analysis of Antibody-drug Conjugates
14.4 Manufacturing Expenses Analysis of Antibody-drug Conjugates
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
1.1 Definition of Antibody-drug Conjugates in This Report
1.2 Commercial Types of Antibody-drug Conjugates
1.2.1 Seattle Genetics technology
1.2.2 ImmunoGen technology
1.2.3 Immunomedics technology
1.3 Downstream Application of Antibody-drug Conjugates
1.3.1 IgG1 antibodies
1.3.2 HER2 antibodies
1.4 Development History of Antibody-drug Conjugates
1.5 Market Status and Trend of Antibody-drug Conjugates 2013-2023
1.5.1 Global Antibody-drug Conjugates Market Status and Trend 2013-2023
1.5.2 Regional Antibody-drug Conjugates Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Antibody-drug Conjugates 2013-2017
2.2 Sales Market of Antibody-drug Conjugates by Regions
2.2.1 Sales Volume of Antibody-drug Conjugates by Regions
2.2.2 Sales Value of Antibody-drug Conjugates by Regions
2.3 Production Market of Antibody-drug Conjugates by Regions
2.4 Global Market Forecast of Antibody-drug Conjugates 2018-2023
2.4.1 Global Market Forecast of Antibody-drug Conjugates 2018-2023
2.4.2 Market Forecast of Antibody-drug Conjugates by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Antibody-drug Conjugates by Types
3.2 Sales Value of Antibody-drug Conjugates by Types
3.3 Market Forecast of Antibody-drug Conjugates by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Antibody-drug Conjugates by Downstream Industry
4.2 Global Market Forecast of Antibody-drug Conjugates by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Antibody-drug Conjugates Market Status by Countries
5.1.1 North America Antibody-drug Conjugates Sales by Countries (2013-2017)
5.1.2 North America Antibody-drug Conjugates Revenue by Countries (2013-2017)
5.1.3 United States Antibody-drug Conjugates Market Status (2013-2017)
5.1.4 Canada Antibody-drug Conjugates Market Status (2013-2017)
5.1.5 Mexico Antibody-drug Conjugates Market Status (2013-2017)
5.2 North America Antibody-drug Conjugates Market Status by Manufacturers
5.3 North America Antibody-drug Conjugates Market Status by Type (2013-2017)
5.3.1 North America Antibody-drug Conjugates Sales by Type (2013-2017)
5.3.2 North America Antibody-drug Conjugates Revenue by Type (2013-2017)
5.4 North America Antibody-drug Conjugates Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Antibody-drug Conjugates Market Status by Countries
6.1.1 Europe Antibody-drug Conjugates Sales by Countries (2013-2017)
6.1.2 Europe Antibody-drug Conjugates Revenue by Countries (2013-2017)
6.1.3 Germany Antibody-drug Conjugates Market Status (2013-2017)
6.1.4 UK Antibody-drug Conjugates Market Status (2013-2017)
6.1.5 France Antibody-drug Conjugates Market Status (2013-2017)
6.1.6 Italy Antibody-drug Conjugates Market Status (2013-2017)
6.1.7 Russia Antibody-drug Conjugates Market Status (2013-2017)
6.1.8 Spain Antibody-drug Conjugates Market Status (2013-2017)
6.1.9 Benelux Antibody-drug Conjugates Market Status (2013-2017)
6.2 Europe Antibody-drug Conjugates Market Status by Manufacturers
6.3 Europe Antibody-drug Conjugates Market Status by Type (2013-2017)
6.3.1 Europe Antibody-drug Conjugates Sales by Type (2013-2017)
6.3.2 Europe Antibody-drug Conjugates Revenue by Type (2013-2017)
6.4 Europe Antibody-drug Conjugates Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Antibody-drug Conjugates Market Status by Countries
7.1.1 Asia Pacific Antibody-drug Conjugates Sales by Countries (2013-2017)
7.1.2 Asia Pacific Antibody-drug Conjugates Revenue by Countries (2013-2017)
7.1.3 China Antibody-drug Conjugates Market Status (2013-2017)
7.1.4 Japan Antibody-drug Conjugates Market Status (2013-2017)
7.1.5 India Antibody-drug Conjugates Market Status (2013-2017)
7.1.6 Southeast Asia Antibody-drug Conjugates Market Status (2013-2017)
7.1.7 Australia Antibody-drug Conjugates Market Status (2013-2017)
7.2 Asia Pacific Antibody-drug Conjugates Market Status by Manufacturers
7.3 Asia Pacific Antibody-drug Conjugates Market Status by Type (2013-2017)
7.3.1 Asia Pacific Antibody-drug Conjugates Sales by Type (2013-2017)
7.3.2 Asia Pacific Antibody-drug Conjugates Revenue by Type (2013-2017)
7.4 Asia Pacific Antibody-drug Conjugates Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Antibody-drug Conjugates Market Status by Countries
8.1.1 Latin America Antibody-drug Conjugates Sales by Countries (2013-2017)
8.1.2 Latin America Antibody-drug Conjugates Revenue by Countries (2013-2017)
8.1.3 Brazil Antibody-drug Conjugates Market Status (2013-2017)
8.1.4 Argentina Antibody-drug Conjugates Market Status (2013-2017)
8.1.5 Colombia Antibody-drug Conjugates Market Status (2013-2017)
8.2 Latin America Antibody-drug Conjugates Market Status by Manufacturers
8.3 Latin America Antibody-drug Conjugates Market Status by Type (2013-2017)
8.3.1 Latin America Antibody-drug Conjugates Sales by Type (2013-2017)
8.3.2 Latin America Antibody-drug Conjugates Revenue by Type (2013-2017)
8.4 Latin America Antibody-drug Conjugates Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Antibody-drug Conjugates Market Status by Countries
9.1.1 Middle East and Africa Antibody-drug Conjugates Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Antibody-drug Conjugates Revenue by Countries (2013-2017)
9.1.3 Middle East Antibody-drug Conjugates Market Status (2013-2017)
9.1.4 Africa Antibody-drug Conjugates Market Status (2013-2017)
9.2 Middle East and Africa Antibody-drug Conjugates Market Status by Manufacturers
9.3 Middle East and Africa Antibody-drug Conjugates Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Antibody-drug Conjugates Sales by Type (2013-2017)
9.3.2 Middle East and Africa Antibody-drug Conjugates Revenue by Type (2013-2017)
9.4 Middle East and Africa Antibody-drug Conjugates Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF ANTIBODY-DRUG CONJUGATES
10.1 Global Economy Situation and Trend Overview
10.2 Antibody-drug Conjugates Downstream Industry Situation and Trend Overview
CHAPTER 11 ANTIBODY-DRUG CONJUGATES MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Antibody-drug Conjugates by Major Manufacturers
11.2 Production Value of Antibody-drug Conjugates by Major Manufacturers
11.3 Basic Information of Antibody-drug Conjugates by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Antibody-drug Conjugates Major Manufacturer
11.3.2 Employees and Revenue Level of Antibody-drug Conjugates Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 ANTIBODY-DRUG CONJUGATES MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 F. Hoffmann-La Roche
12.1.1 Company profile
12.1.2 Representative Antibody-drug Conjugates Product
12.1.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche
12.2 Seattle Genetics
12.2.1 Company profile
12.2.2 Representative Antibody-drug Conjugates Product
12.2.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of Seattle Genetics
12.3 Takeda Pharmaceuticals
12.3.1 Company profile
12.3.2 Representative Antibody-drug Conjugates Product
12.3.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of Takeda Pharmaceuticals
12.4 AbbVie
12.4.1 Company profile
12.4.2 Representative Antibody-drug Conjugates Product
12.4.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of AbbVie
12.5 AbGenomics
12.5.1 Company profile
12.5.2 Representative Antibody-drug Conjugates Product
12.5.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of AbGenomics
12.6 ADC Therapeutics
12.6.1 Company profile
12.6.2 Representative Antibody-drug Conjugates Product
12.6.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of ADC Therapeutics
12.7 Agensys
12.7.1 Company profile
12.7.2 Representative Antibody-drug Conjugates Product
12.7.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of Agensys
12.8 ALMAC Group
12.8.1 Company profile
12.8.2 Representative Antibody-drug Conjugates Product
12.8.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of ALMAC Group
12.9 Ambrx
12.9.1 Company profile
12.9.2 Representative Antibody-drug Conjugates Product
12.9.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of Ambrx
12.10 Astellas Pharma
12.10.1 Company profile
12.10.2 Representative Antibody-drug Conjugates Product
12.10.3 Antibody-drug Conjugates Sales, Revenue, Price and Gross Margin of Astellas Pharma
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTIBODY-DRUG CONJUGATES
13.1 Industry Chain of Antibody-drug Conjugates
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF ANTIBODY-DRUG CONJUGATES
14.1 Cost Structure Analysis of Antibody-drug Conjugates
14.2 Raw Materials Cost Analysis of Antibody-drug Conjugates
14.3 Labor Cost Analysis of Antibody-drug Conjugates
14.4 Manufacturing Expenses Analysis of Antibody-drug Conjugates
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
